Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model

Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma‐associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 80; no. 5; pp. 781 - 790
Main Authors Cormier, Janice N., Panelli, Monica C., Hackett, Julia A., Bettinotti, Maria P., Mixon, Arnold, Wunderlich, John, Parker, Linda L., Restifo, Nicholas P., Ferrone, Soldano, Marincola, Francesco M.
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.03.1999
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma‐associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by HLA class I–restricted cytotoxic T cells (CTLs). However, the relevance of down‐regulation remains in question in terms of frequency of occurrence. Moreover the functional significance of epitope down‐regulation, defining the relationship between MHC/epitope density and CTL interactions, is a matter of controversy, particularly with regard to whether the noted variability of expression of MHC/epitope occurs within a range likely to affect target recognition by CTLs. In this study, bulk metastatic melanoma cell lines originated from 25 HLA‐A*0201 patients were analyzed for expression of HLA‐A2 and MAAs. HLA‐A2 expression was heterogeneous and correlated with lysis by CTLs. Sensitivity to lysis was also independently affected by the amount of ligand available for binding at concentrations of 0.001 to 1 mM. Natural expression of MAA was variable, independent from the expression of HLA‐A*0201, and a significant co‐factor determining recognition of melanoma targets. Thus, the naturally occurring variation in the expression of MAA and/or HLA documented by our in vitro results modulates recognition of melanoma targets and may (i) partially explain CTL–target interactions in vitro and (ii) elucidate potential mechanisms for progressive escape of tumor cells from immune recognition in vivo. Int. J. Cancer: 80, 781–790 (1999). © 1999 Wiley‐Liss, Inc.
AbstractList Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma-associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by HLA class I-restricted cytotoxic T cells (CTLs). However, the relevance of down-regulation remains in question in terms of frequency of occurrence. Moreover the functional significance of epitope down-regulation, defining the relationship between MHC/epitope density and CTL interactions, is a matter of controversy, particularly with regard to whether the noted variability of expression of MHC/epitope occurs within a range likely to affect target recognition by CTLs. In this study, bulk metastatic melanoma cell lines originated from 25 HLA-A*0201 patients were analyzed for expression of HLA-A2 and MAAs. HLA-A2 expression was heterogeneous and correlated with lysis by CTLs. Sensitivity to lysis was also independently affected by the amount of ligand available for binding at concentrations of 0.001 to 1 mM. Natural expression of MAA was variable, independent from the expression of HLA-A*0201, and a significant co-factor determining recognition of melanoma targets. Thus, the naturally occurring variation in the expression of MAA and/or HLA documented by our in vitro results modulates recognition of melanoma targets and may (i) partially explain CTL-target interactions in vitro and (ii) elucidate potential mechanisms for progressive escape of tumor cells from immune recognition in vivo.
Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma-associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by HLA class I–restricted cytotoxic T cells (CTLs). However, the relevance of down-regulation remains in question in terms of frequency of occurrence. Moreover the functional significance of epitope down-regulation, defining the relationship between MHC/epitope density and CTL interactions, is a matter of controversy, particularly with regard to whether the noted variability of expression of MHC/epitope occurs within a range likely to affect target recognition by CTLs. In this study, bulk metastatic melanoma cell lines originated from 25 HLA-A*0201 patients were analyzed for expression of HLA-A2 and MAAs. HLA-A2 expression was heterogeneous and correlated with lysis by CTLs. Sensitivity to lysis was also independently affected by the amount of ligand available for binding at concentrations of 0.001 to 1 mM. Natural expression of MAA was variable, independent from the expression of HLA-A*0201, and a significant co-factor determining recognition of melanoma targets. Thus, the naturally occurring variation in the expression of MAA and/or HLA documented by our in vitro results modulates recognition of melanoma targets and may (i) partially explain CTL–target interactions in vitro and (ii) elucidate potential mechanisms for progressive escape of tumor cells from immune recognition in vivo .
Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma‐associated antigens (MAAs), which may lead to tumor escape from immune recognition. Loss of expression of HLA class I or MAA has, as an undisputed consequence, loss of recognition by HLA class I–restricted cytotoxic T cells (CTLs). However, the relevance of down‐regulation remains in question in terms of frequency of occurrence. Moreover the functional significance of epitope down‐regulation, defining the relationship between MHC/epitope density and CTL interactions, is a matter of controversy, particularly with regard to whether the noted variability of expression of MHC/epitope occurs within a range likely to affect target recognition by CTLs. In this study, bulk metastatic melanoma cell lines originated from 25 HLA‐A*0201 patients were analyzed for expression of HLA‐A2 and MAAs. HLA‐A2 expression was heterogeneous and correlated with lysis by CTLs. Sensitivity to lysis was also independently affected by the amount of ligand available for binding at concentrations of 0.001 to 1 mM. Natural expression of MAA was variable, independent from the expression of HLA‐A*0201, and a significant co‐factor determining recognition of melanoma targets. Thus, the naturally occurring variation in the expression of MAA and/or HLA documented by our in vitro results modulates recognition of melanoma targets and may (i) partially explain CTL–target interactions in vitro and (ii) elucidate potential mechanisms for progressive escape of tumor cells from immune recognition in vivo. Int. J. Cancer: 80, 781–790 (1999). © 1999 Wiley‐Liss, Inc.
Author Mixon, Arnold
Restifo, Nicholas P.
Cormier, Janice N.
Bettinotti, Maria P.
Marincola, Francesco M.
Wunderlich, John
Parker, Linda L.
Hackett, Julia A.
Ferrone, Soldano
Panelli, Monica C.
AuthorAffiliation 2 HLA Laboratory, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
3 Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA
1 Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
AuthorAffiliation_xml – name: 1 Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA
– name: 2 HLA Laboratory, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
– name: 3 Department of Microbiology and Immunology, New York Medical College, Valhalla, NY, USA
Author_xml – sequence: 1
  givenname: Janice N.
  surname: Cormier
  fullname: Cormier, Janice N.
– sequence: 2
  givenname: Monica C.
  surname: Panelli
  fullname: Panelli, Monica C.
– sequence: 3
  givenname: Julia A.
  surname: Hackett
  fullname: Hackett, Julia A.
– sequence: 4
  givenname: Maria P.
  surname: Bettinotti
  fullname: Bettinotti, Maria P.
– sequence: 5
  givenname: Arnold
  surname: Mixon
  fullname: Mixon, Arnold
– sequence: 6
  givenname: John
  surname: Wunderlich
  fullname: Wunderlich, John
– sequence: 7
  givenname: Linda L.
  surname: Parker
  fullname: Parker, Linda L.
– sequence: 8
  givenname: Nicholas P.
  surname: Restifo
  fullname: Restifo, Nicholas P.
– sequence: 9
  givenname: Soldano
  surname: Ferrone
  fullname: Ferrone, Soldano
– sequence: 10
  givenname: Francesco M.
  surname: Marincola
  fullname: Marincola, Francesco M.
  email: marincola@nih.gov.
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1667174$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/10048982$$D View this record in MEDLINE/PubMed
BookMark eNpVkk1v1DAQhi1URLeFv4B8QKg9ZPFHnMQLKorCR4NW7IEicbOcZLI1Suwlzi7sv8fpbks52R4_845m5j1DJ9ZZQOg9JXNKCHtz8a0syktKZBoRRsUFlVISTuhlRhbiXZrRxSIvP0Tll4LFV3xO5sXqLYvyJ2j2kHOCZkGJRCnlySk68_4nIZQKEj9Dp6FGnMmMzdD-qx63g-7wTg9Gj8ZZ7Fo83gKGP5sBvD9Grpc51rbBYBu3Buu2PjxHE664d8220yN4XNws8QC1W1tzp2RsgHBp8c6Mg8M9dNq6Xk8Z0D1HT1vdeXhxPM_R908fb4rraLn6XBb5MtrwlMWRqCrd1EnSCpa0kIiYVY1Ma95ykTWEcF6nAhhQwSvgmogYqhYayRmHNgknP0dXB93NtuqhqcGOoV-1GUyvh71y2qj_f6y5VWu3U4ykTHIRBF4fBQb3awt-VL3xNXShGQhzUIkUKcukDODLx5UeStxPOwCvjoD2te7aQdva-H9ckqQ0jQP244D9Nh3sH8lMSkxN1lDTmtW0ZnVvDZURJVSwhgrOUHfOUFwRVawUU_khwP8C-N21GQ
CODEN IJCNAW
ContentType Journal Article
Copyright Copyright © 1999 Wiley‐Liss, Inc.
1999 INIST-CNRS
Copyright_xml – notice: Copyright © 1999 Wiley‐Liss, Inc.
– notice: 1999 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 790
ExternalDocumentID 10048982
1667174
IJC24
Genre article
Journal Article
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: Z99 CA999999
– fundername: Intramural NIH HHS
  grantid: Z01 BC010763-01
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AHBTC
AHMBA
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
SUPJJ
UB1
UDS
V2E
V8K
V9Y
VH1
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
X7M
XG1
XPP
XV2
ZGI
ZZTAW
~IA
~WT
8WZ
A6W
ABEFU
ABEML
ACBWZ
ACSCC
ACXME
AHEFC
ASPBG
AVWKF
AZFZN
BDRZF
C45
EMOBN
FEDTE
GLUZI
HF~
HVGLF
IQODW
M6P
OVD
PALCI
RYL
SAMSI
TEORI
Y6R
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-p3724-5bbadc66f526fe6542bd97c3f358d0033c75e2e153be3a054ebfed9323ef6d933
IEDL.DBID DR2
ISSN 0020-7136
IngestDate Tue Sep 17 21:06:23 EDT 2024
Sat Aug 17 04:21:14 EDT 2024
Sat Sep 28 08:39:07 EDT 2024
Sun Jul 28 03:31:46 EDT 2024
Sat Aug 24 00:54:18 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Human
HLA-System
Immune response
Tumor associated antigen
Major histocompatibility system
Variability
Melanoma
Cytotoxicity
Cellular immunity
Tumoral marker
Malignant tumor
In vitro
Established cell line
T-Lymphocyte
Class I histocompatibility antigen
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p3724-5bbadc66f526fe6542bd97c3f358d0033c75e2e153be3a054ebfed9323ef6d933
Notes This article is a US Government work and, as such, is in the public domain in the United States of America
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 10048982
PQID 69572899
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2072935
proquest_miscellaneous_69572899
pubmed_primary_10048982
pascalfrancis_primary_1667174
wiley_primary_10_1002_SICI_1097_0215_19990301_80_5_781_AID_IJC24_3_0_CO_2_A_IJC24
PublicationCentury 1900
PublicationDate 1 March 1999
PublicationDateYYYYMMDD 1999-03-01
PublicationDate_xml – month: 03
  year: 1999
  text: 1 March 1999
  day: 01
PublicationDecade 1990
PublicationPlace New York
PublicationPlace_xml – name: New York
– name: New York, NY
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 1999
Publisher John Wiley & Sons, Inc
Wiley-Liss
Publisher_xml – name: John Wiley & Sons, Inc
– name: Wiley-Liss
References 1995; 92
1996; 19
1995; 16
1994; 152
1994; 153
1995; 55
1996b; 19
1997; 89
1997
1997; 18
1996; 4
1995; 154
1997; 3
1998; 75
1996a; 19
1996; 66
1996; 88
References_xml – volume: 153
  start-page: 1225
  year: 1994
  end-page: 1237
  article-title: Loss of HLA haplotype and B locus down‐regulation in melanoma cell lines
  publication-title: J. Immunol
– volume: 75
  start-page: 517
  year: 1998
  end-page: 524
  article-title: Heterogeneous expression of melanoma‐associated antigens (MAA) and HLA‐A2 in metastatic melanoma
  publication-title: Int. J. Cancer
– volume: 89
  start-page: 319
  year: 1997
  end-page: 321
  article-title: Low frequency of ErbB‐2 protooncogene overexpression in human leukocyte antigen A2 positive breast cancer patients
  publication-title: J. nat. Cancer Inst
– volume: 92
  start-page: 8125
  year: 1995
  end-page: 8129
  article-title: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development
  publication-title: Proc. nat. Acad. Sci. USA
– volume: 19
  start-page: 192
  year: 1996a
  end-page: 205
  article-title: Analysis of expression of the melanoma associated antigens MART‐1 and gp100 in metastatic melanoma cell lines and in lesions
  publication-title: J. Immunother
– volume: 16
  start-page: 487
  year: 1995
  end-page: 494
  article-title: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance
  publication-title: Immunol. Today
– volume: 152
  start-page: 2393
  year: 1994
  end-page: 2400
  article-title: Association of HER2/neu expression with sensitivity to tumor‐specific CTL in human ovarian cancer
  publication-title: J. Immunol
– volume: 88
  start-page: 100
  year: 1996
  end-page: 108
  article-title: The loss of functional b2‐microglobulin in metastatic melanomas from five patients undergoing immunotherapy
  publication-title: J. nat. Cancer Inst
– volume: 152
  start-page: 163
  year: 1994
  end-page: 175
  article-title: Scheme for ranking potential HLA‐A2 binding peptides based on independent binding of individual peptide side‐chains
  publication-title: J. Immunol
– volume: 19
  start-page: 375
  year: 1996
  end-page: 380
  article-title: Expression of gp100 in melanoma metastases resected before and after treatment with IFNα and IL‐2
  publication-title: J. Immunother
– volume: 66
  start-page: 470
  year: 1996
  end-page: 476
  article-title: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 cytotoxic T‐cell responses: evidence for immunoselection of antigen‐loss variants
  publication-title: Int. J. Cancer
– year: 1997
– volume: 55
  start-page: 3149
  year: 1995
  end-page: 3157
  article-title: Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes
  publication-title: Cancer Res
– volume: 4
  start-page: 565
  year: 1996
  end-page: 571
  article-title: Evidence that a single peptide–MHC complex on a target cell can elicit a cytolytic T cell response
  publication-title: Immunity
– volume: 154
  start-page: 3961
  year: 1995
  end-page: 3968
  article-title: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor‐infiltrating T lymphocytes associated with tumor regression
  publication-title: J. Immunol
– volume: 18
  start-page: 175
  year: 1997
  end-page: 182
  article-title: Cancer vaccines based on the identification of genesencoding cancer regression antigens
  publication-title: Immunol. Today
– volume: 3
  start-page: 37
  year: 1997
  end-page: 44
  article-title: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART‐1/MelanA
  publication-title: Cancer J. Sci. Am
– volume: 19
  start-page: 266
  year: 1996b
  end-page: 277
  article-title: Differential anti‐MART‐1/MelanA CTL activity in peripheral blood of HLA‐A2 melanoma patients in comparison to healthy donors: evidence for priming by tumor cells
  publication-title: J. Immunother
– volume: 19
  start-page: 357
  year: 1996
  end-page: 363
  article-title: Differences in frequency distribution of HLA‐A2 sub‐types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols
  publication-title: J. Immunother
SSID ssj0011504
Score 1.9047697
Snippet Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma‐associated antigens (MAAs), which may...
Increasing attention has been devoted to elucidating the mechanism of lost or decreased expression of MHC or melanoma-associated antigens (MAAs), which may...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 781
SubjectTerms Antibodies, Monoclonal
Antigens, Neoplasm
Biological and medical sciences
Breast Neoplasms - pathology
Cells, Cultured
Cytotoxicity, Immunologic
Epitopes - immunology
Female
Genetic Variation
Histocompatibility Antigens Class I - biosynthesis
Histocompatibility Antigens Class I - genetics
Histocompatibility Testing
HLA-A Antigens - genetics
Host-tumor relations. Immunology. Biological markers
Humans
Lymphocytes, Tumor-Infiltrating - immunology
Major Histocompatibility Complex
Medical sciences
Melanoma - immunology
Melanoma-Specific Antigens
Neoplasm Proteins - genetics
T-Lymphocytes, Cytotoxic - immunology
Tumor Cells, Cultured
Tumors
Title Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291097-0215%2819990301%2980%3A5%3C781%3A%3AAID-IJC24%3E3.0.CO%3B2-A
https://www.ncbi.nlm.nih.gov/pubmed/10048982
https://search.proquest.com/docview/69572899
https://pubmed.ncbi.nlm.nih.gov/PMC2072935
Volume 80
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLamPUy8cL8UGPiBSttDutSOnaQgUAmb2mkXAZu0N8uJbVFBk6ntJkDir_BbOSdOsxV4RUiRkjiJj-J8x_mcHH-HkBciZTLPdREYyaIgSp0N0txFgWWoJJJyGTmcnHx4JEen0f6ZOFsjP5ZzYbw-RPvBDT2j7q_RwXU-37kSDQUC9nGcjWHAjD9Rg7BWSUhwVj2yfChOQnjIosuzOOnDFizD8btgvJ-xqMt3eS_sZcdd_pYFQ-jBUYoPKdWHVnwKqVKj4RwGMJSTG-RNY31nCy1vt3a3lla3k3AgXoG9waC19dpbegl2MPBSz6HtnU-a8TdW-2dw5nXSXL_19m6Rn8v28sEun3sXi7xXfP9NSvK_NehtcrPh03ToHeAOWbPlXbJx2EQM3CPfjnStLEIv9cyjkFaOAuul9msTA1yXjA6GVJeG2tJUXrcWdhcoVUqnlcEcZ3ZOs5MD2kZcwXWTEk6i45JeThazik7tF11WU03r9EL3yene7kk2Cpp0E8E5jwGoAjBrCimdYNJZTOSVmzQuuOMiMZjzroiFZRZeEbnlGqiuzZ01wH-5dRLW_AFZL6vSPiLUJYb3o8IAH8sjw2UCXSdQJcYB_Vqm_Q7ZXAGCOvfSIqovJYyvow55vgSGAnfHfzi6tHDrSqYixjFyhzz0MLm6FDvjNGEdEq8AqD0BhcRXj5STT7WgOEP5eC465H2Nj2tVYq1MISyaUAUAhVpCQiWhEgrAoAAHqsaB4ipU2bFiaugLHv-DOp-QG148AyMBn5L1xezCbgI1XOTPag_-BcmpRhc
link.rule.ids 230,315,786,790,891,1382,27955,27956,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1db9MwFLXGkAYvfH8UGPMDlbaHdKkdO0lBoJJtakbbCeikvVlJ7IgKmkxdNwEP_BX-KvfGabYCrwgpUhIn8VWcc53j5PpcQl6IkMk0TTJHS-Y5XpgbJ0xzzzEMlURCLr0cJyePxnJw7B2eiJM18mM5F8bqQzQf3NAzqv4aHRw_SO9eqoYCA_sYRzGMmPEvquNWMgkBTqtHmg_FgQtPWbR55Add2IKlH-858WHEvDbf5x23Ex21-Vvm9K-R69BhCHTsvQ-N_BSSpVrF2XVgMCc3yJva_O42mt5pDG8vze4Ebk-8AoO9XmPstTX1Egxh6GVyBq2f27QZf-O1f4ZnXqXN1Xvv4Db5uWwxG-7yuXO-SDvZ99_EJP9fk94ht2pKTfvWB-6SNVPcIxujOmjgPvk2TipxEXqRzC0QaZlTIL7UfK3DgKuSwbBPk0JTU-jSStfC7gLVSums1JjmzJzRaDKkTdAVXDct4CQaF_RiupiXdGa-JEU5S2iVYegBOT7Yn0QDp8444ZxyH7AqALY6kzIXTOYGc3mlOvQznnMRaEx7l_nCMANvidTwBNiuSXOjgQJzk0tY84dkvSgL85jQPNC862UaKFnqaS4D6D2BLTEODpDIsNsimytIUKdWXUR1pYQhttciW0tkKPB4_I2TFAZuXclQ-DhMbpFHFieXl2J_HAasRfwVBDUnoJb46pFi-qnSFGeoIM9Fi7yvAHKlSqyVKYRFHa0AoFBLSKjAVUIBGBTgQFU4UFy5KjpSTPVtwZN_UOcWuTGYjIZqGI_fPSU3rZYGBgY-I-uL-bnZBKa4SJ9X7vwLTCdKNw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGkCpeuF8CjPmBSttDutROnKQgUElXNaPruGzS3qwktkUFTaqumwCJv8Jv5ZwkzVbgFSFFauImPqr7Hec7yfF3CHnuhUykaZLZSjDXdkOj7TA1rq0ZKomEXLgGFycfTsToxD049U43yI_VWphKH6J54IaeUc7X6OBzZfYuRUOBgH2MoxgCZnyJajulSkKAq-qR5UNz4MCf7LV55Add2IOtHw_s-CBibpvv847TiY7a_A2z-9fIdVdwhrHb4EOjPoVcqRZxdmyI5USLvK7N7-2g6d3G8M7K7G7g9LyXYLDXa4y9qky9AEOYeZmcweCbqmrG32jtn9mZV1lzedsb3iI_VwNWZbt87pwv0072_Tctyf82orfJzZpQ037lAXfIhs7vktZhnTJwj3ybJKW0CL1IFhUMaWEo0F6qv9ZJwGXLaNynSa6ozlVRCdfC4RK1SumsUFjkTJ_R6HhMm5QruG6aw0k0zunFdLko6Ex_SfJiltCyvtB9cjLcP45Gdl1vwp5zH5DqAWhVJoTxmDAaK3mlKvQzbrgXKCx6l_meZhruEanmCXBdnRqtgABzbQR88gdkMy9y_YhQEyjedTMFhCx1FRcBzJ3AlRgH-Cci7Fpkaw0Icl5pi8iuEBBguxbZXgFDgr_jS5wk1_DTpQg9H4NkizysYHJ5Kc7GYcAs4q8BqDkBlcTXv8mnn0pFcYb68dyzyPsSH1e6xF6ZRFjUuQoACrmChAwc6UkAgwQcyBIHkktHRkeSyX7V8Pgf9LlNWu8GQzmOJ2-fkBuVkAZmBT4lm8vFud4CmrhMn5XO_AsK-Ejm
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+variation+of+the+expression+of+HLA+and+endogenous+antigen+modulates+CTL+recognition+in+an+In+vitro+melanoma+model&rft.jtitle=International+journal+of+cancer&rft.au=Cormier%2C+Janice+N.&rft.au=Panelli%2C+Monica+C.&rft.au=Hackett%2C+Julia+A.&rft.au=Bettinotti%2C+Maria+P.&rft.date=1999-03-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=80&rft.issue=5&rft.spage=781&rft.epage=790&rft_id=info:doi/10.1002%2F%28SICI%291097-0215%2819990301%2980%3A5%3C781%3A%3AAID-IJC24%3E3.0.CO%3B2-A&rft.externalDBID=10.1002%252F%2528SICI%25291097-0215%252819990301%252980%253A5%253C781%253A%253AAID-IJC24%253E3.0.CO%253B2-A&rft.externalDocID=IJC24
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon